Creative Medical Technology Holdings Identifies Novel Mechanism of Action of AmnioStem™ Adult Stem Cell Product in Stroke

Advertisement

BEGIN ARTICLE PREVIEW:

PHOENIX, Aug. 20, 2020 /PRNewswire/ — Creative Medical Technology Holdings Inc., trading under the ticker symbol CELZ, announced today new data demonstrating effective suppression of stroke associated pathological molecules by AmnioStem® universal donor stem cells.  
Experiments have shown that AmnioStem® potently blockes production of cytokines which are associated with brain damage after stroke. In contrast to previously attempted approaches, the data disclosed today demonstrate that AmnioStem® effectively reprograms the macrophages from a pathological to a reparative role.
“The brain damage that occurs in stroke is an ongoing process that only begins when the blood supply is occluded.  Even after the blocked artery is resolved, an inflammatory cascade initiates that causes ongoing brain damage.” Said Thomas Ichim, Ph.D, Chief Scientific Officer of the Company. “Macrophages are key players in causing brain damage after a stroke. The fact that AmnioStem® makes macrophages switch from an inflammatory to anti-inflammatory phenotype suggests superior advantages to other regenerative approaches towards this terrible condition.”
Previous studies performed by the Company at its BioLabs research facility in San Diego, showed that AmnioStem® cells were superior at suppressing production of inflammatory mediators such as TNF-alpha, interferon gamma, and interleukin-12 as compared to other stem cells1.  The current studies show …

END ARTICLE PREVIEW

READ MORE FROM SOURCE ARTICLE